ALDH1A3 and ovarian carcinoma: Given its involvement in various pathological conditions including breast cancer, glioblastoma, and epithelial ovarian cancer, ALDH1A3 has emerged as a compelling target for the development of novel therapeutic agents and as a potential prognostic biomarker [23].